BURNABY, BC, July 19, 2021 /CNW/ - Symvivo Corporation today announced that it is receiving advisory services and research and development funding of up to $4.57 million from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) to support the clinical advancement of bacTRL-Spike™, the company's orally administered vaccine candidate for the prevention of COVID-19 and the expansion of the bacTRL platform towards additional vaccine targets.
Symvivo Corporation, a clinical-stage biotechnology company advancing a proprietary bacTRL™ gene delivery platform, announced today that it has entered into a research collaboration with Janssen Biotech, Inc. (Janssen), one of the Pharmaceutical Companies of Johnson & Johnson. Under the terms of the agreement, Janssen will have the exclusive option to research, develop and commercialize novel biological therapeutic candidates based on Symvivo’s bacTRL™ platform technology. The agreement was facilitated by Johnson & Johnson Innovation.
Symvivo has enrolled and dosed the first healthy volunteer in a Phase I trial in Australia to evaluate its oral Covid-19 vaccine candidate, bacTRL-Spike.
BURNABY, British Columbia — Symvivo Corporation, a clinical-stage biotechnology company advancing a proprietary bacTRL™ gene delivery platform, today announced the enrollment and dosing of the first healthy volunteer in a clinical trial in Australia evaluating its bacTRL-Spike™ oral vaccine candidate for the prevention of COVID-19.
BURNABY, British Columbia--(BUSINESS WIRE)--Symvivo Corporation today announced that it is receiving advisory services and funding of up to $2.8 million from the National Research Council Industrial Research Assistance Program (NRC IRAP) to support the clinical advancement of bacTRL-Spike™, the company’s oral, room temperature-stable DNA vaccine candidate for the prevention of COVID-19.